Yiyi Gong

Yiyi Gong

Auto-generated profile, based on publicly available information

Yiyi Gong

Department of Endocrinology, NHC Key Laboratory of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 November 2022 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
XNXiaolin Ni
Xiaolin Ni
WLWei Liu
Wei Liu
DZDingding Zhang
Dingding Zhang
XLXiang Li
Xiang Li
YCYue Chi
Yue Chi
WXWeibo Xia
Weibo Xia
Context Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused by excessive production of fibroblast growth factor 23 (FGF23) by a tumor. Hyperparathyroidism (HPT) including secondary HPT (SHPT) and tertiary HPT (THPT) in TIO patients, which is considered to associate with phosphate supplementation, has not been well documented. Objectives To clarify the prevalence, clinical characteristics, and risk factors for HPT in a large cohort of Chinese TIO patients in our hospital. Design, Setting and Participants This retrospective study enrolled 202 TIO patients. Main outcome measurements Occurrence of HPT in TIO patients. Results HPT was observed in 91 patients (91/202, 45.1%), as 84 patients (41.6%) were diagnosed as SHPT and seven patients (3.5%) were diagnosed as THPT. All patients with THPT underwent parathyroidectomy and only one patient experienced recurrence. Compared with patients without HPT, patients with SHPT had longer disease duration, higher rate of phosphate and calcitriol supplementation, lower serum calcium, lower urine calcium excretion, and higher urine phosphate excretion. Compared with patients with SHPT, patients with THPT had even longer disease duration, higher rate of phosphate and calcitriol supplementation. PTH levels showed positive correlation with intact FGF23 and 1,25(OH)2D levels, but not 25OHD level in TIO patients. Multivariate logistic regression analysis showed that long disease duration and phosphate supplementation were independently associated with occurrence of HPT in TIO patients. Further logistic regression analysis and restricted cubic spline model revealed dose-response relationship between cumulative dose of phosphate supplementation and PTH levels. Conclusions HPT is common in our TIO patients. To avoid the occurrence of HPT in TIO patients, timely diagnosis and tumor resection is necessary, and excessive dose of phosphate supplementation is not suggested before surgery.

7 September 2024 in Phytomedicine
Verified
Journal Article
Closed access
WSWei Song
Wei Song
BZBingjia Zhao
Bingjia Zhao
QWQunli Wu
Qunli Wu
YGYiyi Gong
Yiyi Gong
YJYifan Jia
Yifan Jia
QZQian Zhang
Qian Zhang

15 May 2023 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
XNXiaolin Ni
Xiaolin Ni
ZZZaizhu Zhang
Zaizhu Zhang
WGWenmin Guan
Wenmin Guan
YCYue Chi
Yue Chi
XLXiang Li
Xiang Li
WXWeibo Xia
Weibo Xia
Context Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused by excessive production of fibroblast growth factor 23 (FGF23) by a tumor. After successful tumor resection, patients could recover from hypophosphatemia quicky. However, data on the changes in bone mineral density (BMD) and microstructure in the short term after surgery remained unclear. Objectives To investigate the postoperative changes in BMD and microstructure in both peripheral and axial bone in TIO patients. Design, Setting, Participants and Main outcome measurements We evaluated BMD and microarchitecture in 22 TIO patients using high-resolution peripheral quantitative computed tomography (HR-pQCT) and dual-energy X-ray absorptiometry (DXA) before and 3 months after surgery in this retrospective study. Results In this study, a total of 22 TIO patients who had recovered serum phosphate levels postoperatively were enrolled. After surgery, areal BMD (aBMD) increased by 21.6% in the femoral neck, by 18.9% in the total hip, and by 29.5% in the lumbar spine. Moreover, TBS increased by 14.1% (all p < 0.001). In contrast, trabecular or cortical volumetric BMD (vBMD), and microstructure of trabecular bone (trabecular number, separation and bone volume ratio) and cortical bone (cortical thickness and porosity) at the distal radius or tibia were further deteriorated. Correlation analyses found that both changes in femoral neck and total hip aBMD were conversely associated with changes in trabecular vBMD and bone volume ratio, while positively correlated with change in trabecular separation at the distal radius. Conclusions Although aBMD and microstructure in the axial bone were improved, vBMD and microstructure in the peripheral bone were further impaired shortly after surgery. Correlation of improvement of aBMD in the total hip and femoral neck with deterioration of vBMD and microstructure at the distal radius indicated shift in calcium from the peripheral bone to the axial bone in the short term after tumor resection in TIO patients.

20 December 2020 in Rheumatology
Verified
Journal Article
Closed access
YGYiyi Gong
Yiyi Gong
PZPanpan Zhang
Panpan Zhang
ZLZheng Liu
Zheng Liu
JLJieqiong Li
Jieqiong Li
HLHui Lu
Hui Lu
WZWen Zhang
Wen Zhang
Objective: The pathogenesis of IgG4-related disease (IgG4-RD) remains unclear. Metabolomic profiling of IgG4-RD patients offers an opportunity to identify novel pathophysiological targets and biomarkers. This study aims to identify potential plasma biomarkers associated with IgG4-RD.Methods: Thirty newly diagnosed IgG4-RD patients, age-matched healthy controls and post-treated IgG4-RD patients were enrolled. Patients’ clinical data, laboratory parameters and plasma were collected. Plasma was measured for ultraperformance liquid chromatography-tandem mass spectrometry based metabolomics and lipidomics profiling. Multivariate and univariate statistical analyses were conducted to identify potential biomarkers. The receiver operating characteristic and the correlations between biomarkers and clinical parameters were investigated.Results: The plasma metabolites are altered among healthy controls, newly diagnosed IgG4-RD and post-treated IgG4-RD groups. Of the identified features, eight metabolites were significantly perturbed in the IgG4-RD group, including glyceric acid 1,3-biphosphate (1,3-BPG), uridine triphosphate (UTP), uridine diphosphate glucose (UDP-Glc) or uridine diphosphate galactose (UDP-Gal), lysophospholipids, linoleic acid derivatives and ceramides. Receiver operating characteristic analysis indicated that UTP, UDP-Glc/UDP-Gal and LysoPC (18:1) had high sensitivity and specificity in diagnosis of IgG4-RD. A Pearson correlation analysis showed that 1,3-BPG and UTP were strongly correlated with clinical parameters.Conclusion: IgG4-RD patients have a unique plasma metabolomic profile compared with healthy controls. Our study suggested that metabolomic profiling may provide important insights into pathophysiology and testable biomarkers for diagnosis of IgG4-RD.

1 January 2021 in Protein Expression and Purification
Verified
Journal Article
Closed access
YGYiyi Gong
Yiyi Gong
MYMeiqi Yi
Meiqi Yi
LZLin Zhang
Lin Zhang
SFShan Feng
Shan Feng
Haiteng DengHaiteng Deng
Haiteng Deng

14 December 2021 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
YGYiyi Gong
Yiyi Gong
XNXiaolin Ni
Xiaolin Ni
CJChenxi Jin
Chenxi Jin
XLXiang Li
Xiang Li
YWYujie Wang
Yujie Wang
WXWeibo Xia
Weibo Xia
Context: Excessive production of fibroblast growth factor 23 (FGF23) by a tumor is considered the main pathogenesis in tumor-induced osteomalacia (TIO). Despite its importance to comprehensive understanding of pathogenesis and diagnosis, the regulation of systemic metabolism in TIO remains unclear. Objective: We aimed to systematically characterize the metabolome alteration associated with TIO. Methods: By means of liquid chromatography–tandem mass spectrometry–based metabolomics, we analyzed the metabolic profile from 96 serum samples (32 from TIO patients at initial diagnosis, pairwise samples after tumor resection, and 32 matched healthy control (HC) subjects). In order to screen and evaluate potential biomarkers, statistical analyses, pathway enrichment and receiver operating characteristic (ROC) were performed. Results: Metabolomic profiling revealed distinct alterations between TIO and HC cohorts. Differential metabolites were screened and conducted to functional clustering and annotation. A significantly enriched pathway was found involving arachidonic acid metabolism. A combination of 5 oxylipins, 4-HDoHE, leukotriene B4, 5-HETE, 17-HETE, and 9,10,13-TriHOME, demonstrated a high sensitivity and specificity panel for TIO prediction screened by random forest algorithm (AUC = 0.951; 95% CI, 0.827-1). Supported vector machine modeling and partial least squares modeling were conducted to validate the predictive capabilities of the diagnostic panel. Conclusion: Metabolite profiling of TIO showed significant alterations compared with HC. A high-sensitivity and high-specificity panel with 5 oxylipins was tested as diagnostic predictor. For the first time, we provide the global profile of metabolomes and identify potential diagnostic biomarkers of TIO. The present work may offer novel insights into the pathogenesis of TIO.